CAR T cell therapy has revolutionized the way certain types of cancer are treated, and the longer those CAR T cells live in a patient's body, the more effectively they respond to cancer. Now, researchers have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers.